Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Clinical Trial Data

Every clinical trial data filing by a US-listed company that our alert engine sent, newest first.

8:33 AM ET 8-K
Clinical Trial Data Arcus Biosciences, Inc. RCUS

Arcus Biosciences Clinical Trial Data

Arcus Biosciences presented new data from its ARC-20 platform study evaluating casdatifan in various treatment lines for clear cell renal cell carcinoma (ccRCC). Key results included a 50% confirmed objective response rate (cORR) for the first-line casdatifan plus zimberelimab combination and a 14.5-month median progression-free survival for the second-line combination with cabozantinib.

7:01 AM ET 8-K
Clinical Trial Data Odyssey Therapeutics, Inc. ODTX

Odyssey Therapeutics Clinical Trial Data

Odyssey Therapeutics announced positive Phase 2a results for its oral RIPK2 inhibitor, OD-001, in patients with moderate-to-severe ulcerative colitis. The trial met its primary endpoint with a 27% clinical remission rate at the 20 mg BID dose at Week 12, showing significant correlation between clinical efficacy and inflammatory biomarkers.

6:35 AM ET 8-K
Clinical Trial Data Quoin Pharmaceuticals Ltd. QNRX

Quoin Pharmaceuticals Clinical Trial Data

Quoin Pharmaceuticals announced the publication of a peer-reviewed case report detailing 21 months of compassionate use treatment with QRX003 in a pediatric Netherton Syndrome patient, showing an improvement from severe to clear skin. The company also reaffirmed that its ongoing Phase 2/3 study of QRX003 expects to complete recruitment by the end of 2026 with topline data anticipated in Q2 2027.

Term
21 months
6:06 AM ET 8-K
Clinical Trial Data Rapport Therapeutics, Inc. RAPP

Rapport Therapeutics Clinical Trial Data

Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania, meeting the primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in the YMRS total score. The drug was well-tolerated with no serious adverse events, establishing clinical proof-of-concept for its novel TARP g8-selective mechanism. The company plans to progress RAP-219 into Phase 3 trials for bipolar mania in the second half of 2027.

4:10 PM ET 8-K
Clinical Trial Data SpyGlass Pharma, Inc. SGP

SpyGlass Pharma Clinical Trial Data

SpyGlass Pharma announced positive 4-year interim results from its first-in-human trial of the BIM-IOL System for glaucoma patients undergoing cataract surgery. The data showed a 37% reduction in mean intraocular pressure and 86% of patients remained off topical drops with no product-related adverse events reported.

Term
4 years
9:06 AM ET 8-K
Clinical Trial Data Veradermics, Inc MANE

Veradermics Clinical Trial Data

Veradermics announced positive topline results from its Phase 3 '304' clinical trial of VDPHL01 for male pattern hair loss, meeting all primary and secondary endpoints with high statistical significance. The study demonstrated robust increases in hair count and rapid onset of activity as early as Month 2, with a favorable safety profile and no treatment-related serious adverse events. These results, combined with prior Phase 2/3 data, support a potential FDA submission for the first non-hormonal oral treatment for pattern hair loss.

Term
6 months
8:08 AM ET 8-K
Clinical Trial Data ArriVent BioPharma, Inc. AVBP

ArriVent BioPharma Clinical Trial Data

ArriVent BioPharma announced the publication of Phase 1b results for firmonertinib in the journal Cancer Cell, focusing on patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC). The data showed a confirmed overall response rate (ORR) of 68% at the 240 mg dose and a median progression-free survival of 16.0 months, supporting the ongoing global Phase 3 ALPACCA trial.

7:08 AM ET 8-K
Clinical Trial Data Disc Medicine, Inc. IRON

Disc Medicine Clinical Trial Data

Disc Medicine announced positive topline results from its pivotal Phase 3 APOLLO trial of bitopertin in patients with erythropoietic protoporphyria (EPP). The trial met all primary and secondary endpoints, including a 41.4% reduction in whole-blood PPIX and a significant increase in pain-free light tolerance, with an NDA resubmission planned by the end of 2026.

Term
6 months

“Today represents a potential breakthrough in the science and treatment of EPP. We could not have hoped for a better outcome, and we are grateful to the patients, caregivers, and physicians who have partnered with us throughout the clinical development of bitopertin.”

John Quisel, J.D., Ph.D., President and Chief Executive Officer

“These results are compelling evidence of the clinical benefit of a mechanism aimed at reducing the production of PPIX, the fundamental cause of disease. It has been an incredible journey from establishing the original hypothesis of targeting heme synthesis in cellular models to seeing that biology translate into the clear and meaningful clinical effects from APOLLO.”

Will Savage, M.D., Ph.D., Chief Medical Officer
7:05 AM ET 8-K
Clinical Trial Data EyePoint, Inc. EYPT

EyePoint Clinical Trial Data

EyePoint announced topline results from LUCIA, its second pivotal Phase 3 clinical trial of DURAVYU for wet age-related macular degeneration (wet AMD). The trial failed to meet its primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to the aflibercept control, although it did meet secondary endpoints related to treatment burden reduction and safety.

7:01 AM ET 8-K
Clinical Trial Data Fractyl Health, Inc. GUTS

Fractyl Health Clinical Trial Data

Fractyl Health announced positive topline six-month results from its REMAIN-1 Pivotal Cohort study evaluating the Revita DMR System for weight maintenance after GLP-1 therapy discontinuation. The study met its six-month co-primary endpoint with high statistical significance (p=0.0023), showing that Revita participants retained 80% of their weight loss compared to 67% for the sham group. The company plans to submit a De Novo marketing application to the FDA in late Q4 2026 based on these results.

5:23 PM ET 8-K
Clinical Trial Data Opus Genetics, Inc. IRD

Opus Genetics Clinical Trial Data

Opus Genetics presented positive clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at the Retina in Rio 2026 conference. OPGx-BEST1 showed improved retinal sensitivity in 75% of Cohort 1 participants, while OPGx-LCA5 demonstrated sustained visual improvements through 24 months in adults and 6 months in pediatric patients.

9:30 AM ET 8-K
Clinical Trial Data bioAffinity Technologies, Inc. BIAF

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its CyPath Lung test and a new investigational test for asthma and COPD-related lung inflammation. The presentation will focus on improving lung cancer risk stratification and managing pulmonary nodules using the company's noninvasive flow cytometry technology.

Counterparty
American College of Chest Physicians
8:00 AM ET 8-K
Clinical Trial Data Jasper Therapeutics, Inc. JSPR

Jasper Therapeutics Clinical Trial Data

Jasper Therapeutics completed enrollment for the IgA nephropathy (IgAN) cohort of its Phase 2 basket study evaluating vensobafusp alfa (KP104). The company expects to report initial interim data from this study by year-end 2026 and plans to expand the study to include patients with focal segmental glomerulosclerosis (FSGS) in early 2027.

7:02 AM ET 8-K
Clinical Trial Data Krystal Biotech, Inc. KRYS

Krystal Biotech Clinical Trial Data

Krystal Biotech announced positive proof-of-concept clinical data from its Gorlin Syndrome Pilot Study evaluating KB113 for the treatment of basal cell carcinomas. The study showed that over 80% of assessed lesions regressed across three patients, including non-injected lesions, suggesting a systemic abscopal effect.

8:52 AM ET 8-K
Clinical Trial Data Aptevo Therapeutics Inc. APVO

Aptevo Therapeutics Clinical Trial Data

Aptevo Therapeutics announced it will present data on its multispecific platform and CD40-directed portfolio at the SITC 2026 Annual Meeting. The presentation will focus on the platform's ability to coordinate innate and adaptive immune activity within the tumor microenvironment to overcome immunosuppression in solid tumors.

Counterparty
Society for Immunotherapy of Cancer (SITC)
8:00 AM ET 8-K
Clinical Trial Data Profound Medical Corp. PROF

Profound Medical Clinical Trial Data

Profound Medical announced the presentation of five abstracts at the 15th Interventional MRI Symposium regarding its TULSA-PRO system. The data included real-world validation from the CARE Registry and Mayo Clinic, as well as results from the CAPTAIN randomized controlled trial showing superior preservation of erectile function compared to robotic radical prostatectomy.

Counterparty
Mayo Clinic
7:52 AM ET 8-K
Clinical Trial Data Entrada Therapeutics, Inc. TRDA

Entrada Therapeutics Clinical Trial Data

Entrada Therapeutics announced positive topline data from Cohort 1 of its Phase 1/2 ELEVATE-45-201 study evaluating ENTR-601-45 in patients with Duchenne Muscular Dystrophy (DMD). The study met its primary objectives of favorable safety and tolerability at the 5 mg/kg dose, with secondary objectives showing a 0.10% mean increase in dystrophin production. The company is currently dosing Cohort 2 at 10 mg/kg and expects to report data from that cohort in the first half of 2027.

6:00 AM ET 8-K
Clinical Trial Data Biomea Fusion, Inc. BMEA

Biomea Fusion Clinical Trial Data

Biomea Fusion announced topline results from its Phase 1 GLP-131 clinical trial evaluating BMF-650, an investigational oral small molecule GLP-1 receptor agonist. The study focused on healthy overweight or obese adult participants over a 4-week period to assess safety and efficacy. The company hosted a conference call and provided an investor presentation to discuss the findings and the potential of BMF-650 in treating obesity and metabolic diseases.

9:23 AM ET 8-K
Clinical Trial Data bioAffinity Technologies, Inc. BIAF

bioAffinity Technologies Clinical Trial Data

bioAffinity Technologies announced it will present positive research data at the CHEST 2026 annual meeting regarding its sputum-based tests for lung inflammation. The data demonstrates the ability to detect multiple protein biomarkers and biologic drug targets for asthma and COPD using the company's flow cytometry and AI platform. The research aims to support a precision medicine approach for identifying patients who could benefit from specific biologic therapies.

Counterparty
American College of Chest Physicians
8:36 AM ET 8-K
Clinical Trial Data CervoMed Inc. CRVO

CervoMed Clinical Trial Data

CervoMed announced positive initial 12-week biomarker data from its Phase 2a clinical trial of neflamapimod in patients with nonfluent variant primary progressive aphasia (nfvPPA). The data showed a mean reduction in plasma neurofilament light chain (NfL) levels, a key marker of neurodegeneration, which contrasts with the increases typically seen in the natural history of the disease.

8:33 AM ET 8-K
Clinical Trial Data First Tracks Biotherapeutics, Inc. TRAX

First Tracks Biotherapeutics Clinical Trial Data

First Tracks Biotherapeutics announced positive topline data from the first Phase 1b cohort of its drug candidate ANB033 for the treatment of Celiac Disease. The company also updated its corporate investor presentation to reflect these clinical developments.

8:25 AM ET 8-K
Clinical Trial Data iBio, Inc. IBIO

iBio Clinical Trial Data

iBio released preclinical body-composition data from an eight-week obese non-human primate (NHP) study of its Activin E antibody candidate, IBIO-610. The study demonstrated that combining IBIO-610 with semaglutide resulted in 93% of weight loss coming from fat compared to 77% for semaglutide alone, suggesting significant muscle preservation potential. The company plans to initiate first-in-human clinical trials in the first half of 2027.

8:09 AM ET 8-K
Clinical Trial Data Mirum Pharmaceuticals, Inc. MIRM

Mirum Pharmaceuticals Clinical Trial Data

Mirum Pharmaceuticals announced positive topline results from its Phase 3 EXPAND study of LIVMARLI (maralixibat) for ultra-rare cholestatic liver diseases, including biliary atresia. The study met its primary endpoint for pruritus improvement and all five secondary endpoints with statistical significance. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in the first half of 2027 based on these results.

6:03 AM ET 8-K
Clinical Trial Data Zenas BioPharma, Inc. ZBIO

Zenas BioPharma Clinical Trial Data

Zenas BioPharma announced new data from its Phase 3 INDIGO trial and open-label extension for obexelimab in patients with IgG4-related disease (IgG4-RD). The findings demonstrated sustained clinical activity with a 93% probability of remaining flare-free over 12 months and a significant reduction in cumulative glucocorticoid toxicity compared to placebo.

9:07 AM ET 8-K
Clinical Trial Data Pulse Biosciences, Inc. PLSE

Pulse Biosciences Clinical Trial Data

Pulse Biosciences reached its enrollment target of 164 evaluable patients in the NANOPULSE-AF IDE pivotal clinical study three months ahead of schedule. The study evaluates the safety and effectiveness of the nPulse Cardiac Catheter System for treating drug-resistant paroxysmal atrial fibrillation. Primary safety and effectiveness endpoints will be assessed at 6 and 12 months post-ablation to support future regulatory submissions.

9:00 AM ET 8-K
Clinical Trial Data BioCardia, Inc. BCDA

BioCardia Clinical Trial Data

BioCardia announced it will present the trial design and scientific support for its CardiAMP HF II Study at the Heart Failure Society of America Annual Scientific Meeting. The study evaluates a high-dose autologous cell treatment for patients with ischemic heart failure of reduced ejection fraction (HFrEF) who remain symptomatic despite medical therapy.

Counterparty
Heart Failure Society of America
9:04 AM ET 8-K
Clinical Trial Data Bluejay Diagnostics, Inc. BJDX

Bluejay Diagnostics Clinical Trial Data

Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study, which is evaluating the Symphony IL-6 Test for mortality risk in sepsis patients. The study includes 777 evaluable patients with an 18% mortality rate, providing a diverse dataset to support the company's planned regulatory submission. The data showed that non-survivors had higher baseline illness severity, with septic shock present in 56.4% of that group.

8:07 AM ET 8-K
Clinical Trial Data ArriVent BioPharma, Inc. AVBP

ArriVent BioPharma Clinical Trial Data

ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant non-small cell lung cancer did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review. While the drug showed clinical benefit in secondary endpoints and a consistent safety profile, it failed to show a statistically significant improvement over chemotherapy. The company is currently evaluating the full dataset to determine the future development path for the candidate.

Counterparty
Allist
8:06 AM ET 8-K
Clinical Trial Data PDS Biotechnology Corp PDSB

PDS Biotechnology Clinical Trial Data

PDS Biotechnology announced it will host a virtual Key Opinion Leader (KOL) event on October 15, 2026, to discuss clinical outcomes from the PDS0301 Phase 2 trials. The event will focus on the metastatic colorectal cancer (mCRC) cohort, specifically patients with unresectable microsatellite stable (MSS) liver metastases, a population where immunotherapy has historically been ineffective.

Counterparty
National Cancer Institute
7:30 AM ET 8-K
Clinical Trial Data Kairos Pharma, LTD. KAPA

Kairos Pharma Clinical Trial Data

Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy demonstrated a statistically significant median progression-free survival of 17.7 months compared to 2 months for apalutamide alone (P=0.0008). Based on these results, the company has modified the trial protocol to enroll patients earlier in the disease progression and targets trial completion by Q4 2027.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.